Holen Sie sich die Stockscreener-App
64.00
4.30%
2.64
Handel nachbörslich:
58.50
-5.50
-8.59%
Disc Medicine Inc Aktie (IRON) Neueste Nachrichten
Disc Medicine to Seek Traditional FDA Approval for Bitopertin After EPP CRL; APOLLO Data Due Q4 - Yahoo Finance
Disc Medicine to pursue traditional U.S. approval after FDA rejects new fast-track route - AOL.com
HC Wainwright Reduces Earnings Estimates for Disc Medicine - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON - PR Newswire
Insider Selling: Disc Medicine (NASDAQ:IRON) CFO Sells $256,154.50 in Stock - MarketBeat
Jean Franchi Sells 7,081 Shares of Disc Medicine (NASDAQ:IRON) Stock - MarketBeat
Disc Medicine: Downgrading As CRL Puts APOLLO Study Into Question (NASDAQ:IRON) - Seeking Alpha
HC Wainwright Predicts Weaker Earnings for Disc Medicine - MarketBeat
Disc Medicine (IRON) Valuation Check After FDA Complete Response Letter On Lead Bitopertin Program - Yahoo Finance
Disc Medicine (IRON) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Disc Medicine eyes standard US approval for drug after FDA denies fast-track nod - WNWN-FM
Analysts Have Conflicting Sentiments on These Healthcare Companies: Crispr Therapeutics AG (CRSP), Moderna (MRNA) and Disc Medicine (IRON) - The Globe and Mail
Disc Medicine (NASDAQ:IRON) Insider William Jacob Savage Sells 3,256 Shares - MarketBeat
Disc Medicine (NASDAQ:IRON) COO Sells $203,100.66 in Stock - MarketBeat
Disc Medicine (NASDAQ:IRON) CEO John Quisel Sells 13,264 Shares - MarketBeat
Insider Selling: Disc Medicine (NASDAQ:IRON) Insider Sells 2,853 Shares of Stock - MarketBeat
Khara, Disc Medicine chief legal officer, sells $179k in shares - Investing.com Australia
Khara, Disc Medicine chief legal officer, sells $179k in shares By Investing.com - Investing.com Canada
Disc Medicine CCO Stephenson sells $347k in shares By Investing.com - Investing.com Canada
Disc Medicine chief medical officer sells $204,672 in stock By Investing.com - Investing.com South Africa
Disc Medicine CCO Stephenson sells $347k in shares - Investing.com
Disc Medicine CEO Quisel sells $833k in shares By Investing.com - Investing.com Canada
Disc Medicine (NASDAQ:IRON) Drives Biotechnology Shifts In Views On Development Strategy - Kalkine Media
Disc Medicine Faces Turbulence as FDA Raises Concerns on Drug Approval - timothysykes.com
Disc Medicine (NASDAQ:IRON) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Stifel cuts Disc Medicine stock price target on FDA setback By Investing.com - Investing.com Canada
Cantor Fitzgerald cuts Disc Medicine stock price target on FDA setback - Investing.com Canada
IRON: Stifel Lowers Price Target to $110, Maintains Buy Rating | - GuruFocus
Disc Medicine’s Stock Dips as FDA Approves Pending Concerns - StocksToTrade
Disc Medicine Plans FDA Response on Bitopertin With Phase 3 Results; Shares Rise - marketscreener.com
Disc Medicine stock slumps after FDA declines approval for inherited disorder drug over efficacy concerns - MSN
Disc Medicine Faces Turmoil Amid FDA Concerns but Investors Not Losing Hope - timothysykes.com
Disc Medicine's Multiple Catalysts Provide Runway Despite Bitopertin Delay, Morgan Stanley Says - marketscreener.com
Wedbush Adjusts Price Target on Disc Medicine to $88 From $110, Maintains Outperform Rating - marketscreener.com
Disc Medicine After The CRL: Risk Now Rests On APOLLO (NASDAQ:IRON) - Seeking Alpha
Wedbush Issues Pessimistic Forecast for Disc Medicine (NASDAQ:IRON) Stock Price - MarketBeat
BMO Capital Markets Issues Pessimistic Forecast for Disc Medicine (NASDAQ:IRON) Stock Price - MarketBeat
Disc Medicine, Inc. (IRON) Stock Report: Analyst Consensus Predicts 84.84% Upside Potential - DirectorsTalk Interviews
IRON: Wells Fargo Lowers Price Target Amidst Maintaining Overwei - GuruFocus
Disc Medicine executives noted during a conference call that the policy debate over accelerated approval pathways has spanned multiple government administrations. - Bitget
Disc Medicine Addresses FDA Rejection of Bitopertin Filing - TipRanks
Disc Medicine outlines FDA CRL for bitopertin, aims to complete APOLLO and respond by late 2026 - TradingView
IRON: FDA requests APOLLO study results for bitopertin approval; decision expected by mid-2027 - TradingView
Disc Medicine Shares Drop 22% Due to FDA Regulatory Setback - Intellectia AI
FDA Delays Disc Medicine's Rare Disease Drug - Bitget
What's Going On With Disc Medicine Stock Tuesday?Disc Medicine (NASDAQ:IRON) - Benzinga
Disc Medicine plunges on FDA complete response letter for bitopertin - MSN
Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA - MedCity News
Disc Medicine (IRON) Faces Setback After FDA Response - GuruFocus
TimesSquare Capital Management LLC Purchases Shares of 182,170 Disc Medicine, Inc. $IRON - MarketBeat
FDA issues complete response letter to Disc Medicine’s bitopertin NDA - Yahoo Finance
Disc Medicine stock plunges after FDA issues Complete Response Letter By Investing.com - Investing.com Australia
FDA slaps CRL on Disc Medicine’s bitopertin NDA - The Pharma Letter
(IRON) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns - Stocktwits
2.25%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):